Ibalizumab, a novel monoclonal antibody for the management of multidrug-resistant HIV-1 infection MV Beccari, BT Mogle, EF Sidman, KA Mastro, E Asiago-Reddy, WD Kufel Antimicrobial agents and chemotherapy 63 (6), 10.1128/aac. 00110-19, 2019 | 92 | 2019 |
Clinical review of delafloxacin: a novel anionic fluoroquinolone BT Mogle, JM Steele, SJ Thomas, KBH Bohan, WD Kufel Journal of Antimicrobial Chemotherapy 73 (6), 1439-1451, 2018 | 68 | 2018 |
Implementation of a two-point pharmacokinetic AUC-based vancomycin therapeutic drug monitoring approach in patients with methicillin-resistant Staphylococcus aureus bacteraemia BT Mogle, JM Steele, RW Seabury, UJ Dang, WD Kufel International journal of antimicrobial agents 52 (6), 805-810, 2018 | 60 | 2018 |
Readiness to implement vancomycin monitoring based on area under the concentration–time curve: a cross-sectional survey of a national health consortium WD Kufel, RW Seabury, BT Mogle, MV Beccari, LA Probst, JM Steele American Journal of Health-System Pharmacy 76 (12), 889-894, 2019 | 54 | 2019 |
Cefiderocol: a novel siderophore cephalosporin for multidrug-resistant Gram-negative bacterial infections KA Parsels, KA Mastro, JM Steele, SJ Thomas, WD Kufel Journal of Antimicrobial Chemotherapy 76 (6), 1379-1391, 2021 | 45 | 2021 |
Real-world, multicenter experience with meropenem-vaborbactam for gram-negative bacterial infections including carbapenem-resistant Enterobacterales and Pseudomonas aeruginosa S Alosaimy, AM Lagnf, T Morrisette, MR Scipione, JJ Zhao, ... Open forum infectious diseases 8 (8), ofab371, 2021 | 38 | 2021 |
Bezlotoxumab: A Novel Agent for the Prevention of Recurrent Clostridium difficile Infection WD Kufel, AS Devanathan, AH Marx, DJ Weber, LM Daniels Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 37 (10 …, 2017 | 36 | 2017 |
Antimicrobial stewardship education in US colleges and schools of pharmacy WD Kufel, MN Jeffres, C MacDougall, JC Cho, AH Marx, DM Williams Journal of Antimicrobial Chemotherapy 73 (8), 2252-2258, 2018 | 33 | 2018 |
Clinical considerations for oral beta-lactams as step-down therapy for Enterobacteriaceae bloodstream infections BT Mogle, MV Beccari, JM Steele, T Fazili, WD Kufel Expert Opinion on Pharmacotherapy 20 (8), 903-907, 2019 | 27 | 2019 |
Clinical review of Clostridium difficile infection: an update on treatment and prevention LM Daniels, WD Kufel Expert opinion on pharmacotherapy 19 (16), 1759-1769, 2018 | 27 | 2018 |
Penicillin allergy assessment and skin testing in the outpatient setting WD Kufel, JA Justo, PB Bookstaver, LM Avery Pharmacy 7 (3), 136, 2019 | 24 | 2019 |
Early multicenter experience with imipenem-cilastatin-relebactam for multidrug-resistant gram-negative infections N Rebold, T Morrisette, AM Lagnf, S Alosaimy, D Holger, K Barber, ... Open Forum Infectious Diseases 8 (12), ofab554, 2021 | 21 | 2021 |
Cefiderocol for treatment of an empyema due to extensively drug-resistant Pseudomonas aeruginosa: clinical observations and susceptibility testing considerations WD Kufel, JM Steele, SW Riddell, Z Jones, P Shakeraneh, TP Endy IDCases 21, e00863, 2020 | 21 | 2020 |
In vivo pharmacokinetic analysis of meropenem/vaborbactam during continuous venovenous haemodialysis WD Kufel, AP Eranki, KM Paolino, A Call, CD Miller, BT Mogle Journal of Antimicrobial Chemotherapy 74 (7), 2117-2118, 2019 | 21 | 2019 |
Pharmacist home visits: A 1-year experience from a community pharmacy SV Monte, SN Passafiume, WD Kufel, P Comerford Jr, DP Trzewieczynski, ... Journal of the American Pharmacists Association 56 (1), 67-72, 2016 | 20 | 2016 |
Antibody-based strategies in HIV therapy WD Kufel International journal of antimicrobial agents 56 (6), 106186, 2020 | 19 | 2020 |
Y-site incompatibility between premix concentrations of vancomycin and piperacillin-tazobactam: do current compatibility testing methodologies tell the whole story? WD Kufel, CD Miller, PR Johnson, K Reid, JJ Zahra, RW Seabury Hospital Pharmacy 52 (2), 132-137, 2017 | 17 | 2017 |
Clinical application and pharmacodynamic monitoring of apixaban in a patient with end‐stage renal disease requiring chronic hemodialysis WD Kufel, AS Zayac, DF Lehmann, CD Miller Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 36 (11 …, 2016 | 16 | 2016 |
Clinical feasibility of monitoring enoxaparin anti-Xa concentrations: are we getting it right? WD Kufel, RW Seabury, W Darko, LA Probst, CD Miller Hospital Pharmacy 52 (3), 214-220, 2017 | 15 | 2017 |
Plasma and cerebrospinal fluid concentrations of cefiderocol during successful treatment of carbapenem-resistant Acinetobacter baumannii meningitis WD Kufel, Y Abouelhassan, JM Steele, RL Gutierrez, T Perwez, ... Journal of Antimicrobial Chemotherapy 77 (10), 2737-2741, 2022 | 14 | 2022 |